STAT+: At AACR, talk of Chinese biotech, oncology’s comms issue, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines showcased daraxonrasib data at the AACR annual meeting, emphasizing activity in frontline pancreatic cancer.
- RM‑055 was introduced as a catalytic inhibitor that removes a phosphate from GTP‑RAS, allowing simultaneous inactivation of multiple mutant RAS proteins.
- Mark Goldsmith said the new drug directly targets the resistance mechanism of mutant RAS amplification, offering a next step in the fight against RAS‑addicted cancers.
Why it matters: Not enough in the article to say why this matters.
